

Ilumya™ (tildrakizumab-asmn)

Last Review Date: November 7, 2018

Number: MG.MM.PH.114av2

Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

Definition

Ilumya (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is a naturally occurring cytokine that is involved in inflammatory and immune responses. Ilumya inhibits the release of pro-inflammatory cytokines and chemokines.

Ilumya (tildrakizumab-asmn) is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Dosing

Max dose (per dose and over time):

- Loading:
 - 100 mg at week 0 and 4
- Maintenance:
 - 100 mg every 12 weeks

Guideline

Ilumya (tildrakizumab-asmn) is considered medically necessary for the following diagnosis when subsequent criteria are met:

Plaque Psoriasis:

- Patient is 18 years of age or older; **AND**
- Patient has been evaluated and screened for the presence of latent TB infection prior to initiating treatment; **AND**
- Patient does not have a clinically important active infection; **AND**
- Patient will not receive live vaccines during therapy; **AND**
- Patient will not concurrently receive treatment with another TNF-inhibitor, biologic response modifier or other non-biologic immunomodulating agent; **AND**
- Patient's baseline disease severity has been assessed by a physician utilizing an objective measure; **AND**
- Patient has had moderate to severe plaque psoriasis for at least 6 months and at least one of the following:
 - Involvement of at least 10% of body surface area (BSA); **OR**
 - Psoriasis Area and Severity Index (PASI) score of 10 or greater; **OR**
 - Incapacitation due to plaque location; **AND**
- Patient has not responded adequately (or is not a candidate) to a 3 month minimum trial of topical agents; **AND**
- Patient has not responded adequately (or is not a candidate) to a 3 month minimum trial of at least 1 systemic agent; **AND**
- Patient has not responded adequately (or is not a candidate) to a 3 month minimum trial of phototherapy
- Patient has a documented failure, or intolerance to, **TWO** of the following:
 - Cosentyx
 - Humira
 - Otezla
 - Stelara SC

Coverage for Ilumya (tildrakizumab-asmn) may be renewed for the following diagnosis when the subsequent criteria are met:

Plaque Psoriasis:

- Patient continues to meet the initial approval criteria above; **AND**
- Absence of unacceptable toxicity from the drug; **AND**
- Patient will receive ongoing monitoring for presence of TB or other active infections: **AND**
- Patient has responded to treatment as indicated by at least one of the following:
 - Improvement in signs and symptoms compared to baseline such as redness, thickness scaliness; **OR**
 - Reduction in the amount of surface area involved; **OR**
 - Improvement on a disease activity scoring tool [e.g. a 75% reduction in the PASI score from when treatment started (PASI 75) or a 50% reduction in the PASI score (PASI 50) and a four point reduction in the DLQI from when treatment started].

Revision History

1/7/2019	Removed JCode J3590, Added JCode J3245. Updated Medical Policy Number
----------	-----------------------------------------------------------------------

Applicable Procedure Codes

J3245	Injection, tildrakizumab-asmn, 1 mg: 1 billable unit = 1 mg
-------	-------------------------------------------------------------

Applicable Diagnosis Codes

L40.0	Psoriasis vulgaris
-------	--------------------

References

1. Ilumya [package insert]. Whitehouse Station, NJ; MSD-Sun Pharmaceuticals; March 2018. Accessed June 2018
2. Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. *Arch dermatol.* 2012 Jan; 148(1):95-102.
3. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. *Ja*
4. National Institute for Health and Care Excellence. NICE 2008. Infliximab for the treatment of adults with psoriasis. Published 23 January 2008. Technology Appraisal Guidance [TA134]. <https://www.nice.org.uk/guidance/ta134/resources/infliximab-for-the-treatment-of-adults-with-psoriasis-pdf-82598103811141>
5. Smith CH, Jabbar-Lopez ZK, Yiu ZK, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. *Br J Dermatol.* 2017 Sep; 177(3):628-636. doi:10.1111/bjd.15665
6. Armstrong AW, Siegel MP, Bagel J, et al. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. *J Am Acad Dermatol.* 2017 Feb; 76(2):290-298. Doi: 10.1016/j.jaad.2018.10.017